Insulet Corporation
Research Insulet Corporation (PODD) on Bullrun: market cap USD 9.92B, P/E 28.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPODD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 9.92B
- P/E28.4
- Financial periodQ2 2026
- RevenueUSD 801.70M
- Net incomeUSD 95.00M
- Free cash flowUSD 51.10M
- Gross margin70.2%
Valuation Snapshot
latest market cap is USD 9.92B; P/E is 28.4.
Peer valuation comparison
Latest P/E is 28.36x versus a Healthcare sector median of 24.46x (15.9% above).
Latest P/E is 28.36x versus a United States median of 24.87x (14.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.71B | USD 247.10M | USD 377.70M | 71.6% | 3.48 | USD 716.10M | USD 18.40M | USD 1.52B |
| FY2024 | USD 2.07B | USD 418.30M | USD 305.30M | 69.8% | 5.78 | USD 953.40M | USD 83.80M | USD 1.21B |
| FY2023 | USD 1.70B | USD 206.30M | USD 70.10M | 68.3% | 2.94 | USD 704.20M | USD 49.40M | USD 732.70M |
| FY2022 | USD 1.06B | USD 4.60M | -USD 3.90M | 76.3% | 0.07 | USD 689.80M | USD 1.40B | USD 476.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.92B | 28.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.01B | 81.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.33B | 45.1 | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.15B | 129.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 20.45B | 1226.6 | n/a | n/a |
| 2021 | 2021-12-31 | USD 18.41B | 1209.4 | n/a | n/a |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Insulet Corporation's market cap?
Insulet Corporation's market capitalization is USD 9.92B.
What is Insulet Corporation's P/E ratio?
Insulet Corporation's price-to-earnings (P/E) ratio is 28.4.
What does Insulet Corporation do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.